Innovative Molecules Begins Phase 2a Trial for Genital Herpes Drug
Innovative Molecules GmbH has started administering its experimental drug, adibelivir, to patients in a Phase 2a clinical trial for recurrent genital herpes. This novel oral treatment is designed to inhibit the herpes simplex virus. This step marks a progression in the company's lead program towards proof-of-concept development.
Want more?
Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.